Traws Pharma Aktie
Marktkapitalisierung
14,47 Mio. $
14,47 Mio. $
Streubesitz
64,45%
KGV
1,12
Index-Zuordnung
-
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.